CRXL » Topics » Research and Development.

This excerpt taken from the CRXL 20-F filed Apr 22, 2009.

Research & Development

 

Our research efforts today are focusing on developing vaccines and antibodies that address unmet medical needs and infectious diseases. Our research efforts are bolstered by our range of technologies, which play a critical role in our development programs. The following pages discuss key developments relating to our discovery programs, as well as providing key areas of focus.

 

 

24


 

Our Business

Research & Development

 

 

25


 

Our Business

Research & Development

 

 

 

Key pipeline developments:

 

·     Successful Phase II results of studies in the US and Philippines of our rabies antibody combination, showing safety and tolerability. Third Phase II study in India in progress.

·     Encouraging results from the Phase I Ad35 tuberculosis vaccine study, showing that CD8 immune responses are considerably higher than ever seen in a tuberculosis vaccine study. Program entered Phase II clinical testing.

 

 

 

 

 

 

·     Alternative adenovirus serotypes like Ad26 and Ad35 using Crucell’s AdVac®/PER.C6® technologies were used to express protein of SIV (HIV-like virus). Study showed strong T-cell immune response and provides protection against SIV. Malaria and TB vaccines in development using Ad26 and Ad35.

·     Crucell’s monoclonal antibodies (mAb) against influenza strongly outperforms the anti-influenza drug oseltamivir in pre-clinical tests.

 

This excerpt taken from the CRXL 20-F filed May 7, 2008.

Research and development

 

Research and development into new and valuable vaccines and proteins is fundamental for the future of our Company. The nature of the business Crucell operates in means that it is critically important we meet high ethical and scientific standards in our work.

 

This excerpt taken from the CRXL 20-F filed Dec 7, 2007.
Research and Development. The Parties jointly shall conduct all the development activities of the Collaboration, as more fully set forth in the-Collaboration and Development Plan and the applicable Annual Plan and Budget.

 

This excerpt taken from the CRXL 20-F filed Jul 6, 2006.

Research and Development

Our research and development spending totaled 32,751, 21,412 and 22,858 for the years 2005, 2004 and 2003, respectively. For a description of our research and development practices and policies, see “Item 4. Information on the Company—Research and Development.”

This excerpt taken from the CRXL 20-F filed Jun 29, 2006.

Research and Development

Our research and development spending totaled 32,751, 21,412 and 22,858 for the years 2005, 2004 and 2003, respectively. For a description of our research and development practices and policies, see “Item 4. Information on the Company—Research and Development.”

This excerpt taken from the CRXL 20-F filed Apr 14, 2005.

Research and Development

        Our research and development spending totaled €20,468, €21,885 and €24,252 for the years 2004, 2003 and 2002, respectively. For a description of our research and development practices and policies, see "Item 4. Information on the Company—Research and Development."

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki